Introduction Non-valvular atrial fibrillation (NVAF) is often accompanied by multiple
comorbid conditions, which increase the associated risks and complexity of patient …

Background and Purpose—Limited evidence exists on the effectiveness and safety of
warfarin and all 4 available non-vitamin K antagonist oral anticoagulants (NOACs) from …

Introduction New oral anticoagulants are non-inferior compared with warfarin regarding
stroke prevention in atrial fibrillation, with similar or decreased risk of bleeding. However, it is …

Purpose The pivotal trials for stroke prevention in non-valvular atrial fibrillation (NVAF)
compared rivaroxaban, dabigatran, and apixaban with warfarin, as did most claims-based …

Discontinuation of oral anticoagulants may expose non-valvular atrial fibrillation (NVAF)
patients to an increased risk of stroke. This study describes the real-world discontinuation …

No studies have performed direct pairwise comparisons of the effectiveness and safety of
warfarin and the new oral anticoagulants (NOACs) apixaban, dabigatran, and rivaroxaban …

Background Apixaban, a non‐vitamin K oral anticoagulant (NOAC), was approved in Japan
in 2012 for the prevention of thromboembolic events in patients with nonvalvular atrial …

Objective: Clinical trials have demonstrated that direct oral anticoagulants (DOACs) are
efficacious in reducing stroke risk among patients with nonvalvular atrial fibrillation (NVAF) …

It remains unknown whether the comparative effectiveness of direct oral anticoagulants
(DOACs) and warfarin differs between atrial fibrillation patients with and without a history of …

Objective: To compare the risk of stroke/systemic embolism (S/SE) and major bleeding (MB)
of elderly (≥ 65 years of age) nonvalvular atrial fibrillation (NVAF) patients initiating …